Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and invasive lymphoma. About 30% of patients are difficult to cure or relapse after R-CHOP treatment, known as relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Patients who are not suitable for high-dose chemotherapy followed by autologous stem cell rescue, rely more on the discovery of new drugs and proposals of new treatment plans. Polatuzumab vedotin (Pola) is an antibody-drug conjugate that targets the B-cell antigen CD79b and delivers monomethyl auristatin E (MMAE). It is recently available in China and approved in combination with Bendamustine and Rituximab for r/r DLBCL. However, real-world data on Pola-based regimens are limited. Here, we propose ZPR (combination of Zanubrutinib, Polatuzumab vedotin and Rituximab) as a potential salvage treatment in r/r DLBCL patients, aiming to explore its efficacy and safety in our single center.